-

Half-Year Liquidity Contract Statement for Valerio Therapeutics

PARIS--(BUSINESS WIRE)--Regulatory News:

Under the liquidity contract entered into between VALERIO THERAPEUTICS (Paris:ALVIO) and Kepler Cheuvreux, the following resources appeared on the liquidity account on June 30, 2024:

- 392,365 shares
- € 144,905.34
- Number of executions on buy side on semester: 108
- Number of executions on sell side on semester: 95
- Traded volume on buy side on semester: 128,013 shares for € 15,133.69
- Traded volume on sell side on semester: 103,822 shares for € 12,955.33

As a reminder:

  • the following resources appeared on the last half year statement on 31 December 2023 on the liquidity account:

- 368,174 shares
- € 144,918.05
- Number of executions on buy side on semester: 324
- Number of executions on sell side on semester: 244
- Traded volume on buy side on semester: 304,205 shares for € 69,976.87
- Traded volume on sell side on semester: 223,191 shares for € 56,117.81

  • the following resources appeared on the liquidity account when the activity started:

- 87,612 shares
- € 196,423.24

The implementation of this report is carried out in accordance with AMF Decision N°2021-01 of June 22, 2021 renewing the implementation of liquidity contracts for shares as an accepted market practice.

Public limited company with a capital of € 21,610,998.20
Registered office: 49 boulevard du Général Martial Valin - 75015 Paris
410 910 095 R.C.S. on the Paris Trade and Companies Register

Contacts

Valerio Therapeutics
Investor Relations
investors@valeriotx.com
tel : +33 (0) 1 70 38 33 99

VALERIO THERAPEUTICS

BOURSE:ALVIO
Release Versions
EnglishFrench

Contacts

Valerio Therapeutics
Investor Relations
investors@valeriotx.com
tel : +33 (0) 1 70 38 33 99

More News From VALERIO THERAPEUTICS

Valerio Therapeutics Announces Binding Offer for the Proposed Acquisition of Etherna Immunotherapies, Creating a Global Leader in Targeted RNA Medicines

VILLEJUIF, France--(BUSINESS WIRE)--Regulatory News: Valerio Therapeutics (FR0010095596 – ALVIO), a biotechnology company pioneering next-generation precision-guided RNA therapeutics ("Valerio" or the "Company"), today announces that it has signed a binding offer for the acquisition of 100% of the share capital of Etherna Immunotherapies NV ("Etherna") (the "Acquisition"). Etherna is a leading technology platform company pioneering the development of mRNA and lipid nanoparticle (LNP) technologi...

Valerio Therapeutics Appoints Gilles Besin as Chief Executive Officer and Announces Results of its Annual General Meeting

VILLEJUIF, France--(BUSINESS WIRE)--Regulatory News: Valerio Therapeutics (FR0010095596 – ALVIO), a clinical-stage biotechnology company pioneering next-generation precision-guided therapeutics (the "Company"), today announces the appointment of Gilles Besin, Ph.D. as Chief Executive Officer by the Board of Directors, effective 1 July 2026, as well as the results of the votes at its shareholders’ general meeting held on 16 June 2026 (the "General Meeting"). The General Meeting approved all reso...

Valerio Therapeutics Announces Binding Term-Sheet for Collaboration and Exclusive License With Seed-Stage Biotech Company

VILLEJUIF, France--(BUSINESS WIRE)--Regulatory News: Valerio Therapeutics (FR0010095596 – ALVIO), a biotechnology company specializing in the development of technology platforms dedicated to the targeted delivery of innovative therapies (the “Company”), announces that it has entered into a binding term-sheet with a biotech company currently operating in stealth mode, setting out the principal terms of a collaboration and exclusive worldwide license. The final terms remains subject to the signin...
Back to Newsroom